Lidocaine Hcl Injection shortage — US supply status & alternatives

Lidocaine Hcl Injection

—

In supply · Australia

LIDOcaine HCl Injection, USP

In supply · 🇦🇺 Australia · short in🇺🇸 US

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Lidocaine Hcl Injection
Brand names	LIDOcaine HCl Injection, USP
Therapeutic category	Auto-created by FDA MedWatch — Drug Safety Alerts scraper

Controlled substance	No

Marketing-authorisation holders	VALESCO PHARMACEUTICALS INC

Registrations on file	1

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Recalls official enforcement reports

🇺🇸

Lidocaine Hcl Injection

Tailstorm Health INC · June 2025

Class IIdetails ↗

🇺🇸

Lidocaine Hcl Injection

Fagron Compounding Services · Aug 2024

Class IIdetails ↗

🇺🇸

Lidocaine Hcl Injection

TAILSTORM HEALTH INC · July 2024

Class IIdetails ↗

🇺🇸

Lidocaine Hcl Injection

Nephron Sterile Compounding Center LLC · June 2022

Class IIdetails ↗

🇺🇸

Lidocaine Hcl Injection

Nephron Sterile Compounding Center LLC · June 2022

Class IIdetails ↗

🇺🇸

Lidocaine Hcl Injection

Nephron Sterile Compounding Center LLC · May 2022

Class IIdetails ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders1 registration · 1 MA holder

Product	Strength	Form	Market	MA holder	Status
Lidocaine Hcl Injection Usp 1%	1%	solution	🇨🇦 CA	VALESCO PHARMACEUTICALS INC	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.